HM Hospitales

Association


Location: Madrid, Spain (ES) ES

ISNI: 0000000458949315

ROR: https://ror.org/01ynvwr63

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study (2023) Köbel M, Kang EY, Weir A, Rambau PF, Lee CH, Nelson GS, Ghatage P, et al. Journal article, Original article MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma (2021) Kang EY, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, et al. Journal article Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) (2020) Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, et al. Journal article Prognostic gene expression signature for high-grade serous ovarian cancer (2020) Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, et al. Journal article Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study (2018) Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, Pharoah PD, et al. Journal article Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity (2017) Van Der Zanden LFM, Vermeulen SH, Oskarsdottir A, Maurits JSF, Diekstra MHM, Ambert V, Cambon-Thomsen A, et al. Journal article Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer (2017) Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, et al. Journal article